Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Does risperidone have a place in the treatment of nonschizophrenic patients?
Autore:
Schweitzer, I;
Indirizzi:
Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia Univ Melbourne Parkville Vic Australia 3052 arkville, Vic 3052, Australia
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 16, anno: 2001,
pagine: 1 - 19
SICI:
0268-1315(200101)16:1<1:DRHAPI>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN REUPTAKE INHIBITORS; BIPOLAR DISORDER; PARKINSONS-DISEASE; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; BEHAVIORAL DISTURBANCES; TOURETTES-SYNDROME; BORDERLINE PERSONALITY; DEPRESSIVE SYNDROME;
Keywords:
risperidone; review; schizophrenia; mood disorder; obsessive-compulsive disorder; dementia; Parkinson's disease;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
81
Recensione:
Indirizzi per estratti:
Indirizzo: Schweitzer, I Melbourne Clin, 130 Church St, Richmond, Vic 3121, AustraliaMelbourne Clin 130 Church St Richmond Vic Australia 3121 lia
Citazione:
I. Schweitzer, "Does risperidone have a place in the treatment of nonschizophrenic patients?", INT CLIN PS, 16(1), 2001, pp. 1-19

Abstract

There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder. These conditions include bipolar disorder, obsessive-compulsive disorder, Tourette's syndrome, dementia, Lewy body disease, mental retardation, Parkinson's disease, idiopathic segmental dystonia and organic catatonia, Although much of the data is anecdotal or in the form of open studies, there isnow emerging a small number of well controlled investigations supporting efficacy for mania, dementia, behavioural disturbance in mental retardation and conduct disorder. Conventional antipsychotics have long been used, either in a primary capacity or as an adjunct to treat these disorders; however, they have limited benefit, pose significant risks of extrapyramidal side-effects, and may cause the potentially life-threatening neuroleptic malignant syndrome. In contrast, risperidone at the recommended low doses may be efficacious and pose reduced risk of motor side-effects. This article reviews the evidence that risperidone may be an effective new treatment for disorders other than schizophrenia, Int Clin Psychopharmacol 16:1-20 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 18:41:07